Parkside Financial Bank & Trust Sells 684 Shares of Johnson & Johnson (NYSE:JNJ)

Parkside Financial Bank & Trust reduced its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 3.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,979 shares of the company’s stock after selling 684 shares during the period. Johnson & Johnson makes up approximately 0.9% of Parkside Financial Bank & Trust’s investment portfolio, making the stock its 22nd biggest position. Parkside Financial Bank & Trust’s holdings in Johnson & Johnson were worth $2,774,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in JNJ. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. Legal & General Group Plc lifted its stake in Johnson & Johnson by 2.3% during the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after purchasing an additional 421,779 shares during the last quarter. FMR LLC lifted its stake in Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Johnson & Johnson by 0.3% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock worth $1,333,545,000 after purchasing an additional 24,505 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on JNJ. Citigroup increased their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Barclays began coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. SVB Leerink dropped their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday. Bank of America dropped their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Finally, Atlantic Securities dropped their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $181.75.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $168.31 on Tuesday. The company has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The stock has a fifty day simple moving average of $176.07 and a 200 day simple moving average of $171.13. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s payout ratio is currently 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the sale, the executive vice president now directly owns 41,813 shares in the company, valued at approximately $7,336,927.11. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the transaction, the executive vice president now directly owns 41,813 shares in the company, valued at approximately $7,336,927.11. The disclosure for this sale can be found here. In the last ninety days, insiders sold 233,611 shares of company stock worth $40,960,735. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.